Victory Capital Management Inc. Decreases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Victory Capital Management Inc. trimmed its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 302,726 shares of the medical equipment provider’s stock after selling 44,869 shares during the quarter. Victory Capital Management Inc. owned approximately 0.44% of Lantheus worth $18,769,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Tucker Asset Management LLC raised its stake in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 282 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 225 shares during the last quarter. Covestor Ltd raised its position in shares of Lantheus by 62.7% during the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 203 shares in the last quarter. Parkside Financial Bank & Trust boosted its holdings in shares of Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 156 shares in the last quarter. Finally, NBC Securities Inc. purchased a new position in shares of Lantheus in the 3rd quarter valued at $46,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Stock Performance

LNTH stock opened at $75.90 on Friday. The stock has a market capitalization of $5.26 billion, a price-to-earnings ratio of 11.59 and a beta of 0.52. The stock’s fifty day moving average is $63.37 and its two-hundred day moving average is $62.97. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The business had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. On average, research analysts predict that Lantheus Holdings, Inc. will post 5.96 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on LNTH. Truist Financial boosted their price target on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Mizuho upped their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. B. Riley lifted their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $99.17.

Insider Transactions at Lantheus

In related news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 94,545 shares of company stock valued at $6,169,936. 2.10% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.